​
​

Vertex Pharmaceuticals (VRTX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Vertex Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$9.84B

Latest Revenue (Q)

$2.77B

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Vertex Pharmaceuticals Revenue by Period

Vertex Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31-10.17%
2022-12-31-17.91%
2021-12-31-22.06%
2020-12-31-49.07%
2019-12-31-36.59%
2018-12-31-22.46%
2017-12-31-46.20%
2016-12-31-64.89%
2015-12-31-77.86%
2014-12-31--52.11%
2013-12-31--20.63%
2012-12-31-8.25%
2011-12-31-883.91%
2010-12-31-40.49%
2009-12-31--41.85%
2008-12-31--11.81%
2007-12-31--8.02%
2006-12-31-34.47%
2005-12-31-56.63%
2004-12-31-48.56%
2003-12-31--57.08%
2002-12-31--3.82%
2001-12-31-114.38%
2000-12-31-26.83%
1999-12-31-38.74%
1998-12-31-1.37%
1997-12-31-229.32%
1996-12-31--39.82%
1995-12-31-12.76%
1994-12-31--29.75%
1993-12-31--

Vertex Pharmaceuticals generated $9.84B in revenue during NA 2023, up 10.17% compared to the previous quarter, and up 322.84% compared to the same period a year ago.

Vertex Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-09-30-5.21%
2024-06-30--1.95%
2024-03-31-6.73%
2023-12-31-1.38%
2023-09-30--0.39%
2023-06-30-4.99%
2023-03-31-3.13%
2022-12-31--1.35%
2022-09-30-6.29%
2022-06-30-4.71%
2022-03-31-1.20%
2021-12-31-4.46%
2021-09-30-10.64%
2021-06-30-4.01%
2021-03-31-5.93%
2020-12-31-5.82%
2020-09-30-0.90%
2020-06-30-0.62%
2020-03-31-7.21%
2019-12-31-48.79%
2019-09-30-0.91%
2019-06-30-9.65%
2019-03-31--1.34%
2018-12-31-10.91%
2018-09-30-4.30%
2018-06-30-17.38%
2018-03-31--1.66%
2017-12-31-12.71%
2017-09-30-6.25%
2017-06-30--23.87%
2017-03-31-55.81%
2016-12-31-10.86%
2016-09-30--4.13%
2016-06-30-8.42%
2016-03-31--4.75%
2015-12-31-34.90%
2015-09-30-86.55%
2015-06-30-19.90%
2015-03-31--4.18%
2014-12-31--19.24%
2014-09-30-29.31%
2014-06-30-16.86%
2014-03-31--66.27%
2013-12-31-58.39%
2013-09-30--28.66%
2013-06-30--5.37%
2013-03-31--1.68%
2012-12-31--0.60%
2012-09-30--19.67%
2012-06-30--4.66%
2012-03-31--22.12%
2011-12-31--14.54%
2011-09-30-476.10%
2011-06-30-55.34%
2011-03-31-12.42%
2010-12-31-175.37%
2010-09-30--24.75%
2010-06-30-40.99%
2010-03-31--33.82%
2009-12-31-35.79%
2009-09-30-30.91%
2009-06-30--20.50%
2009-03-31--26.92%
2008-12-31-3.80%
2008-09-30--54.46%
2008-06-30-66.55%
2008-03-31--

Vertex Pharmaceuticals generated $2.77B in revenue during Q3 2024, up 5.21% compared to the previous quarter, and up 111.18% compared to the same period a year ago.

Vertex Pharmaceuticals Revenue Breakdown

Vertex Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
ORKAMBI-----
SYMDEKO/SYMKEVI-----
TRIKAFTA/KAFTRIO-----
KALYDECO-----
Product-----
Collaborative and Royalty-----
TRIKAFTA-----

Vertex Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (50.00%), TRIKAFTA/KAFTRIO (45.32%), KALYDECO (2.41%), ORKAMBI (1.65%), and SYMDEKO/SYMKEVI (0.62%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
TRIKAFTA/KAFTRIO--------------------
ORKAMBI--------------------
SYMDEKO/SYMKEVI--------------------
KALYDECO--------------------
Collaborative and Royalty--------------------
TRIKAFTA--------------------
Product--------------------

Vertex Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: TRIKAFTA/KAFTRIO (100.00%).

Vertex Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
Outside the United States-----
Other Countries Outside of the United States and Europe-----
Europe-----
UNITED STATES-----

Vertex Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (44.10%), Outside the United States (27.95%), Europe (22.70%), and Other Countries Outside of the United States and Europe (5.25%).

Quarterly Revenue by Country

CountrySep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Other, Non U.S.--------------------
Europe--------------------
Non-US--------------------
UNITED STATES--------------------

Vertex Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (44.74%), Non-US (27.63%), Europe (22.13%), and Other, Non U.S. (5.50%).

Vertex Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
REGNRegeneron Pharmaceuticals--
VRTXVertex Pharmaceuticals--
MRNAModerna--
BNTXBioNTech SE--
BMRNBioMarin Pharmaceutical--
ALNYAlnylam Pharmaceuticals--
SRPTSarepta Therapeutics--
PTCTPTC Therapeutics--
BEAMBeam Therapeutics--
CRSPCRISPR Therapeutics--
DNAGinkgo Bioworks--
KRYSKrystal Biotech--
NTLAIntellia Therapeutics--
CRBUCaribou Biosciences--
VERVVerve Therapeutics--
EDITEditas Medicine--
VKTXViking Therapeutics--
MDGLMadrigal Pharmaceuticals--

VRTX Revenue FAQ

What is Vertex Pharmaceuticals’s yearly revenue?

Vertex Pharmaceuticals's yearly revenue for 2023 was $9.84B, representing an increase of 10.17% compared to 2022. The company's yearly revenue for 2022 was $8.93B, representing an increase of 17.91% compared to 2021. VRTX's yearly revenue for 2021 was $7.57B, representing an increase of 22.06% compared to 2020.

What is Vertex Pharmaceuticals’s quarterly revenue?

Vertex Pharmaceuticals's quarterly revenue for Q3 2024 was $2.77B, a 5.21% increase from the previous quarter (Q2 2024), and a 11.61% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $2.63B, a -1.95% decrease from the previous quarter (Q1 2024), and a 5.68% increase year-over-year (Q2 2023). VRTX's quarterly revenue for Q1 2024 was $2.69B, a 6.73% increase from the previous quarter (Q4 2023), and a 13.15% increase year-over-year (Q1 2023).

What is Vertex Pharmaceuticals’s revenue growth rate?

Vertex Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 29.90%, and for the last 5 years (2019-2023) was 136.35%.

What are Vertex Pharmaceuticals’s revenue streams?

Vertex Pharmaceuticals's revenue streams in c 23 are ORKAMBI, SYMDEKO/SYMKEVI, TRIKAFTA/KAFTRIO, KALYDECO, and Product. ORKAMBI generated $326M in revenue, accounting 1.65% of the company's total revenue, down -36.17% year-over-year. SYMDEKO/SYMKEVI generated $123M in revenue, accounting 0.62% of the company's total revenue, down -31.67% year-over-year. TRIKAFTA/KAFTRIO generated $8.94B in revenue, accounting 45.32% of the company's total revenue, up 16.36% year-over-year. KALYDECO generated $475.5M in revenue, accounting 2.41% of the company's total revenue, down -14.05% year-over-year. Product generated $9.87B in revenue, accounting 50.00% of the company's total revenue, up 137.20% year-over-year.

What is Vertex Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Vertex Pharmaceuticals was Product. This segment made a revenue of $9.87B, representing 50.00% of the company's total revenue.